Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study
Allergology International · 2023
DOI: 10.1016/j.alit.2023.02.002 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergology International, 2023. Verfasst von Tomoo Fukuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Electronic address: fukuda@saitama-med.ac.jp. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Complement C1 Inhibitor Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent attacks of angioedema. HAE types I and II result from deficient or dysfunctional C1-esterase inhibitor (C1-INH). This Phase 3 study assessed the efficacy, pharmacokinetics (PK), and safety of subcutaneous (SC) C1-INH in Japanese patients with HAE. METHODS: The prospective, open-label, multicenter, single-arm Phase 3 study recruited patients with HAE types I or II to an initial run-in period, followed by a 16-week treatment period where patients received 60 IU/kg C1-INH (SC) twice weekly. The two primary endpoints were the time-normalized number of HAE attacks per month and C1-INH functional activity at Week 16. RESULTS: Nine patients entered the treatment period and completed the study. Treatment with C1-INH (SC) significantly reduced the mean monthly attack rate from 3.7 during the run-in period to 0.3 during treatment (exploratory p value of within-patient comparison = 0.004). After the last dose of C1-INH (SC) at Week 16, the mean trough concentration of C1-INH was 59.8%, and the mean area under the plasma concentration-time curve to the end of the dosing period and to the last sample were 5317.1 and 13,091.5 h•%, respectively. During the study, there were no deaths, serious adverse events, or adverse events leading to study discontinuation. CONCLUSIONS: C1-INH (SC) (60 IU/kg twice weekly) was efficacious and well tolerated as a prophylaxis against HAE attacks in Japanese patients with HAE types I or II, which was supported by the increased and maintained C1-INH functional activity. EudraCT Number 2019-003921-99; JapicCTI-205273.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Electronic address: fukuda@saitama-med.ac.jp.
- Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan.
- Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
- Department of Respiratory Medicine, Clover Hospital, Kanagawa, Japan.
- Department of Gastroenterology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Department of Hematology, Heart-Life Hospital, Okinawa, Japan.
Zitieren
APA
Fukuda, T., Yamagami, K., Kawahata, K., Suzuki, Y., Sasaki, Y., Miyagi, T., Jacobs, I., Lawo, J. P., Glassman, F., Akama, H., Hide, M., & Ohsawa, I. (2023). Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study. Allergology International. https://doi.org/10.1016/j.alit.2023.02.002
Vancouver
Fukuda T, Yamagami K, Kawahata K, Suzuki Y, Sasaki Y, Miyagi T, et al. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study. Allergology International. 2023. doi:10.1016/j.alit.2023.02.002
BibTeX
@article{Fukuda2023,
author = {Fukuda, Tomoo and Yamagami, Keiko and Kawahata, Kimito and Suzuki, Yuzo and Sasaki, Yoshihiro and Miyagi, Takashi and Jacobs, Iris and Lawo, John-Philip and Glassman, Fiona and Akama, Hideto and Hide, Michihiro and Ohsawa, Isao},
title = {Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study},
journal = {Allergology International},
year = {2023},
doi = {10.1016/j.alit.2023.02.002}
}
EUVIMED